These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

84 related articles for article (PubMed ID: 27121672)

  • 1. Pharmacokinetic Studies of Cysteamine Bitartrate Delayed-Release.
    Dohil R; Rioux P
    Clin Pharmacol Drug Dev; 2013 Apr; 2(2):178-85. PubMed ID: 27121672
    [TBL] [Abstract][Full Text] [Related]  

  • 2. The Effect of Food on Cysteamine Bitartrate Absorption in Healthy Participants.
    Dohil R; Cabrera BL; Gangoiti J; Rioux P
    Clin Pharmacol Drug Dev; 2012 Oct; 1(4):170-4. PubMed ID: 27121459
    [TBL] [Abstract][Full Text] [Related]  

  • 3. A Phase 1 Pharmacokinetic Study of Cysteamine Bitartrate Delayed-Release Capsules Following Oral Administration with Orange Juice, Water, or Omeprazole in Cystinosis.
    Armas D; Holt RJ; Confer NF; Checani GC; Obaidi M; Xie Y; Brannagan M
    Adv Ther; 2018 Feb; 35(2):199-209. PubMed ID: 29411268
    [TBL] [Abstract][Full Text] [Related]  

  • 4. Halitosis in cystinosis patients after administration of immediate-release cysteamine bitartrate compared to delayed-release cysteamine bitartrate.
    Besouw M; Tangerman A; Cornelissen E; Rioux P; Levtchenko E
    Mol Genet Metab; 2012 Sep; 107(1-2):234-6. PubMed ID: 22832073
    [TBL] [Abstract][Full Text] [Related]  

  • 5. Pharmacokinetics of enteric-coated cysteamine bitartrate in healthy adults: a pilot study.
    Gangoiti JA; Fidler M; Cabrera BL; Schneider JA; Barshop BA; Dohil R
    Br J Clin Pharmacol; 2010 Sep; 70(3):376-82. PubMed ID: 20716238
    [TBL] [Abstract][Full Text] [Related]  

  • 6. The effect of food and liquid pH on the integrity of enteric-coated beads from cysteamine bitartrate delayed-release capsules.
    Pavloff N; Hauser TA; Williams C; Isbell SL; Cadieux B; Johnson M
    Drug Des Devel Ther; 2018; 12():2795-2804. PubMed ID: 30233142
    [TBL] [Abstract][Full Text] [Related]  

  • 7. A randomized controlled crossover trial with delayed-release cysteamine bitartrate in nephropathic cystinosis: effectiveness on white blood cell cystine levels and comparison of safety.
    Langman CB; Greenbaum LA; Sarwal M; Grimm P; Niaudet P; Deschênes G; Cornelissen E; Morin D; Cochat P; Matossian D; Gaillard S; Bagger MJ; Rioux P
    Clin J Am Soc Nephrol; 2012 Jul; 7(7):1112-20. PubMed ID: 22554716
    [TBL] [Abstract][Full Text] [Related]  

  • 8. Effects of food intake on the pharmacokinetic properties of mirabegron oral controlled-absorption system: a single-dose, randomized, crossover study in healthy adults.
    Lee J; Zhang W; Moy S; Kowalski D; Kerbusch V; van Gelderen M; Sawamoto T; Grunenberg N; Keirns J
    Clin Ther; 2013 Mar; 35(3):333-41. PubMed ID: 23497763
    [TBL] [Abstract][Full Text] [Related]  

  • 9. Evaluation of the effects of formulation and food on the pharmacokinetics of lenvatinib (E7080) in healthy volunteers.
    Shumaker R; Aluri J; Fan J; Martinez G; Ren M; Chen K
    Int J Clin Pharmacol Ther; 2014 Apr; 52(4):284-91. PubMed ID: 24548978
    [TBL] [Abstract][Full Text] [Related]  

  • 10. Relative bioavailability of tizanidine 4-mg capsule and tablet formulations after a standardized high-fat meal: a single-dose, randomized, open-label, crossover study in healthy subjects.
    Henney HR; Shah J
    Clin Ther; 2007 Apr; 29(4):661-9. PubMed ID: 17617289
    [TBL] [Abstract][Full Text] [Related]  

  • 11. Twice-daily cysteamine bitartrate therapy for children with cystinosis.
    Dohil R; Fidler M; Gangoiti JA; Kaskel F; Schneider JA; Barshop BA
    J Pediatr; 2010 Jan; 156(1):71-75.e1-3. PubMed ID: 19775699
    [TBL] [Abstract][Full Text] [Related]  

  • 12. A novel sustained-release cysteamine bitartrate formulation for the treatment of cystinosis: Pharmacokinetics and safety in healthy male volunteers.
    Berends CL; Pagan L; van Esdonk MJ; Klarenbeek NB; Bergmann KR; Moerland M; van der Wel V; de Visser SJ; Büller H; de Loos F; de Vries WS; Waals H; de Leede LGJ; Burggraaf J; Kamerling IMC
    Pharmacol Res Perspect; 2021 Apr; 9(2):e00739. PubMed ID: 33764642
    [TBL] [Abstract][Full Text] [Related]  

  • 13. Long-term treatment of cystinosis in children with twice-daily cysteamine.
    Dohil R; Gangoiti JA; Cabrera BL; Fidler M; Schneider JA; Barshop BA
    J Pediatr; 2010 May; 156(5):823-7. PubMed ID: 20138296
    [TBL] [Abstract][Full Text] [Related]  

  • 14. Differential pharmacokinetics of diclofenac potassium for oral solution vs immediate-release tablets from a randomized trial: effect of fed and fasting conditions.
    Chen C; Bujanover S; Kareht S; Rapoport AM
    Headache; 2015 Feb; 55(2):265-75. PubMed ID: 25546369
    [TBL] [Abstract][Full Text] [Related]  

  • 15. A systematic literature review of cysteamine bitartrate in the treatment of nephropathic cystinosis.
    Medic G; van der Weijden M; Karabis A; Hemels M
    Curr Med Res Opin; 2017 Nov; 33(11):2065-2076. PubMed ID: 28692321
    [TBL] [Abstract][Full Text] [Related]  

  • 16. Cysteamine bitartrate delayed-release capsules control leukocyte cystine levels and promote statural growth and kidney health in an open-label study of treatment-naïve patients <6 years of age with nephropathic cystinosis.
    Vaisbich MH; Caires Ferreira J; Price H; Young KD; Sile S; Checani G; Langman CB
    JIMD Rep; 2022 Jan; 63(1):66-79. PubMed ID: 35028272
    [TBL] [Abstract][Full Text] [Related]  

  • 17. Pharmacokinetics of cysteamine bitartrate following gastrointestinal infusion.
    Fidler MC; Barshop BA; Gangoiti JA; Deutsch R; Martin M; Schneider JA; Dohil R
    Br J Clin Pharmacol; 2007 Jan; 63(1):36-40. PubMed ID: 17229040
    [TBL] [Abstract][Full Text] [Related]  

  • 18. Enteric-Coated Cysteamine Bitartrate in Cystinosis Patients.
    Klank S; van Stein C; Grüneberg M; Ottolenghi C; Rauwolf KK; Grebe J; Reunert J; Harms E; Marquardt T
    Pharmaceutics; 2023 Jun; 15(7):. PubMed ID: 37514038
    [TBL] [Abstract][Full Text] [Related]  

  • 19. Evaluation of the effect of 3 different diets on the bioavailability of 2 sustained release theophylline matrix tablets.
    Gai MN; Isla A; Andonaegui MT; Thielemann AM; Seitz C
    Int J Clin Pharmacol Ther; 1997 Dec; 35(12):565-71. PubMed ID: 9455715
    [TBL] [Abstract][Full Text] [Related]  

  • 20. A study of the relative bioavailability of cysteamine hydrochloride, cysteamine bitartrate and phosphocysteamine in healthy adult male volunteers.
    Tennezé L; Daurat V; Tibi A; Chaumet-Riffaud P; Funck-Brentano C
    Br J Clin Pharmacol; 1999 Jan; 47(1):49-52. PubMed ID: 10073739
    [TBL] [Abstract][Full Text] [Related]  

    [Next]    [New Search]
    of 5.